Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04340180
PHASE1

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

Sponsor: University of Alabama at Birmingham

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the ability of AI to correctly aid in characterization of benign and malignant lesions even when a low dose of gadolinium is administered. This study is relevant for several reasons, most notably being the reduction of MRI dose and decreased gadolinium deposition in the brain. In addition, use of AI may provide increased sensitivity and specificity for the radiologist evaluating a breast MRI exam. Half of the population will have benign pathologies and the other half will have malignant pathologies.

Key Details

Gender

FEMALE

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2021-07-14

Completion Date

2026-01-20

Last Updated

2026-07-01

Healthy Volunteers

No

Interventions

DRUG

Standard of Care (SOC) gadolinium Breast MRI

Standard of Care (SOC) gadolinium Breast MRI

DRUG

reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.

reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.

Locations (1)

The Kirklin Clinic

Birmingham, Alabama, United States